GLP-1/glucagon receptor co-agonism for treatment of obesity
Open accessThe DOI matches its Crossref record; 97 of the 97 references it cites were found in a registry or an index.
Abstract
Over a relatively short period, obesity and type 2 diabetes have come to represent a large medical and economic burden to global societies. The epidemic rise in the prevalence of obesity has metabolic consequences and is paralleled by an increased occurrence of other diseases, such as diabetes, cancer and cardiovascular complications. Together, obesity and type 2 diabetes constitute one of the more preventable causes of premature death and the identification of novel, safe and effective anti-obesity drugs is of utmost importance. Pharmacological attempts to treat obesity have had limited success, with notable adverse effects, rendering bariatric surgery as the only current therapy for substantially improving body weight. Novel unimolecular, multifunctional peptides have emerged as one of the most promising medicinal approaches to enhance metabolic efficacy and restore normal body weight. In this review, we will mainly focus on the discovery and translational relevance of dual agonists that pharmacologically function at the receptors for glucagon and glucagon-like peptide-1. Such peptides have advanced to clinical evaluation and inspired the pursuit of multiple related approaches to achieving polypharmacy within single molecules.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This is achieved by enhancing the metabolic rate through the stimulation of hepatic glucose production and activating thermogenic pathways in brown adipose tissue [31].”
From Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta‐Analysis of Randomised Controlled Trials (2026) · cites this paper as [31]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“They work primarily by increasing energy expenditure and promoting weight loss independently of GLP‐1‐mediated appetite suppression.”
From Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta‐Analysis of Randomised Controlled Trials (2026) · cites this paper as [31]
The cited source says what the claim attributes to it.
In the citing paper
“Combining both glucagon receptor and GLP-1 receptor agonism in a single molecule could target weight loss through multiple mechanisms of action to enhance the level of weight loss possible [18].”
In the citing paper
“Since the activation of these pathways sometimes produces opposite effects, the concurrent action on two or more of them could result in a complementary and synergistic effect [154].”
From GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives (2023) · cites this paper as [154]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Positional cloning of the mouse obese gene and its human homologue
Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L., & Friedman, J. M. (1994) · Nature · doi:10.1038/372425a0 · Cited by 13,419
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 1×
“Similarly, recent long-term studies of liraglutide and semaglutide, focusing on cardiovascular outcomes in individuals with type 2 diabetes, reveal a similar incidence of pancreatitis between groups treated with the GLP-1R agonists and placebo [31, 41].”
BackgroundSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 1×
“Similarly, recent long-term studies of liraglutide and semaglutide, focusing on cardiovascular outcomes in individuals with type 2 diabetes, reveal a similar incidence of pancreatitis between groups treated with the GLP-1R agonists and placebo [31, 41].”
BackgroundGlobal estimates of diabetes prevalence for 2013 and projections for 2035
Guariguata, L., Whiting, D. R., Hambleton, I., Beagley, J., Linnenkamp, U., & Shaw, J. E. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.11.002 · Cited by 4,642 · cited 1×
“5% of the global population) [4] and this number is expected to rise to 592 million by 2035 [5].”
BackgroundBiology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 3×
“cially in response to meals high in fat and carbohydrates [14].”
BackgroundInfluentialLixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409 · cited 1×
“In this regard, clinical study of lixisenatide in individuals with type 2 diabetes and acute coronary syndrome did not reveal an association with pancreatitis [40].”
BackgroundChang, S.-H., Stoll, C. R. T., Song, J., Varela, J. E., Eagon, C. J., & Colditz, G. A. (2014) · JAMA Surgery · doi:10.1001/jamasurg.2013.3654 · Cited by 1,688 · cited 1×
“At the other extreme, bariatric surgeries are highly effective in reducing body weight and improving glucose tolerance in most individuals [7, 8].”
BackgroundMedical Consequences of Obesity
Bray, G. A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0535 · Cited by 1,538
Heymsfield, S. B., Greenberg, A. S., Fujioka, K., Dixon, R. M., Kushner, R., Hunt, T., Lubina, J. A., Patane, J., Self, B., Hunt, P., et al. (1999) · JAMA · doi:10.1001/jama.282.16.1568 · Cited by 1,422 · cited 1×
“hyperleptinaemic, develop central leptin resistance and are unresponsive to leptin therapy [72].”
BackgroundPharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3415 · Cited by 1,347 · cited 2×
“However, these therapies are commonly accompanied by adverse gastrointestinal and cardiovascular effects that limit their use [12].”
Background
Research works printed but not linked: 2
- Roglic G World Health Organization Global report on diabetes 2016 Geneva World Health Organization
- Lao J Hansen BC Dimarchi R Pocai A Effect of GLP1R/GCGR dual agonist in monkeys Diabetes 2013 62 A257 A257
Cited by
Incretin hormones: Their role in health and disease
Nauck, M. A., & Meier, J. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13129 · Cited by 950
G protein-coupled receptors: structure- and function-based drug discovery
Yang, D., Zhou, Q., Labroska, V., Qin, S., Darbalaei, S., Wu, Y., Yuliantie, E., Xie, L., Tao, H., Cheng, J., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00435-w · Cited by 632
Glucagon-like peptide 1 in health and disease
Andersen, A., Lund, A., Knop, F. K., & Vilsbøll, T. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0016-2 · Cited by 543
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
Sanyal, A. J., Bedossa, P., Fraessdorf, M., Neff, G. W., Lawitz, E., Bugianesi, E., Anstee, Q. M., Hussain, S. A., Newsome, P. N., Ratziu, V., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2401755 · Cited by 528
Emerging Targets in Type 2 Diabetes and Diabetic Complications
Demir, S., Nawroth, P. P., Herzig, S., & Ekim Üstünel, B. (2021) · Advanced Science · doi:10.1002/advs.202100275 · Cited by 525
Pharmacotherapy of obesity: an update on the available medications and drugs under investigation
Chakhtoura, M., Haber, R., Ghezzawi, M., Rhayem, C., Tcheroyan, R., & Mantzoros, C. S. (2023) · eClinicalMedicine · doi:10.1016/j.eclinm.2023.101882 · Cited by 462
Signaling pathways in obesity: mechanisms and therapeutic interventions
Wen, X., Zhang, B., Wu, B., Xiao, H., Li, Z., Li, R., Xu, X., & Li, T. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01149-x · Cited by 410
“To achieve equivalent efficacy using a noninvasive strategy, researchers have envisioned a “co-agonist” blueprint combining GLP-1R agonists with GCGR agonists or GIPR agonists, or both.(555) In rodents, combined GLP-1 and glucagon administration increased c-Fos expression in the brainstem and amygdala and exhibited a…”
MethodCoskun, T., Urva, S., Roell, W. C., Qu, H., Loghin, C., Moyers, J. S., O’Farrell, L. S., Briere, D. A., Sloop, K. W., Thomas, M. K., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.07.013 · Cited by 316
Nevola, R., Epifani, R., Imbriani, S., Tortorella, G., Aprea, C., Galiero, R., Rinaldi, L., Marfella, R., & Sasso, F. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021703 · Cited by 286
Advances in therapeutic peptides targeting G protein-coupled receptors
Davenport, A. P., Scully, C. C. G., de Graaf, C., Brown, A. J. H., & Maguire, J. J. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0062-z · Cited by 275
GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach
Wang, J.-Y., Wang, Q.-W., Yang, X.-Y., Yang, W., Li, D.-R., Jin, J.-Y., Zhang, H.-C., & Zhang, X.-F. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1085799 · Cited by 248
Glucagon Receptor Signaling and Lipid Metabolism
Galsgaard, K. D., Pedersen, J., Knop, F. K., Holst, J. J., & Wewer Albrechtsen, N. J. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00413 · Cited by 218
“Currently glucagon receptor agonists, combined with GLP-1 and GIP receptor agonists, are investigated as possible therapeutic agents (Gu et al., 2011; Sadry and Drucker, 2013; Sanchez-Garrido et al., 2017; Capozzi et al., 2018).”
BackgroundDrug therapy in obesity: a review of current and emerging treatments
Williams, D. M., Nawaz, A., & Evans, M. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00816-y · Cited by 195
Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review
Cariou, B., Byrne, C. D., Loomba, R., & Sanyal, A. J. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14322 · Cited by 168
“effects from glucagon receptor agonism, while allowing beneficial effects such as increased energy expenditure, satiety, hepatic lipolysis and fatty acid oxidation.(131,132)”
BackgroundTillner, J., Posch, M. G., Wagner, F., Teichert, L., Hijazi, Y., Einig, C., Keil, S., Haack, T., Wagner, M., Bossart, M., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13494 · Cited by 164
Diabetic Nephropathy: Pathogenesis, Mechanisms, and Therapeutic Strategies
Dwivedi, S., & Sikarwar, M. S. (2024) · Hormone and Metabolic Research · doi:10.1055/a-2435-8264 · Cited by 169
“Complementing these pharmacological advances are Gluca - gon-like peptide-1 (GLP-1) agonists, which have emerged as prom - ising candidates for cardiovascular and renal protection in patients with diabetes [36, 37].”
Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice
Knerr, P. J., Mowery, S. A., Douros, J. D., Premdjee, B., Hjøllund, K. R., He, Y., Kruse Hansen, A. M., Olsen, A. K., Perez-Tilve, D., DiMarchi, R. D., et al. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101533 · Cited by 152
“After an initial flurry of preclinical reports highlighting additive effects on weight reduction (for a review, see [20]), data from clinical trials of once-daily GLP-1R/GcgR co-agonists cotadutide (previously MEDI0382) [21e23] and SAR425899 [24,25] have generated guarded optimism over the modest effects on weight red…”
BackgroundSelf-citationNovel Noninvasive Approaches to the Treatment of Obesity: From Pharmacotherapy to Gene Therapy
Angelidi, A. M., Belanger, M. J., Kokkinos, A., Koliaki, C. C., & Mantzoros, C. S. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab034 · Cited by 128
Emerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases
Clemmensen, C., Finan, B., Müller, T. D., DiMarchi, R. D., Tschöp, M. H., & Hofmann, S. M. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0118-x · Cited by 134
Self-citationObesity–An Update on the Basic Pathophysiology and Review of Recent Therapeutic Advances
Gjermeni, E., Kirstein, A., Kolbig, F., Kirchhof, M., Bundalian, L., Katzmann, J. L., Laufs, U., Blüher, M., Garten, A., & Duc, D. L. (2021) · Biomolecules · doi:10.3390/biom11101426 · Cited by 157
The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease
Romero, F. A., Jones, C. T., Xu, Y., Fenaux, M., & Halcomb, R. L. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01701 · Cited by 120
Nauck, M. A., Tuttle, K. R., Tschöp, M. H., & Blüher, M. (2026) · The Lancet · doi:10.1016/s0140-6736(25)02105-1 · Cited by 123
Self-citationArjmand, G., Abbas-Zadeh, M., & Eftekhari, M. H. (2022) · Scientific Reports · doi:10.1038/s41598-021-04258-9 · Cited by 111
Muzurović, E. M., Volčanšek, Š., Zibar, K., Janež, A., Mikhailidis, D. P., Rizzo, M., & Mantzoros, C. S. (2022) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484221146371 · Cited by 126
Seghieri, M., Christensen, A. S., Andersen, A., Solini, A., Knop, F. K., & Vilsbøll, T. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00649 · Cited by 92
“However, novel dual receptor agonists have been developed for the treatment of obesity and T2D under the concept that GLP-1 restrains the hyperglycemic action of glucagon, while allowing it to exert its beneficial actions on bodyweight, food intake, lipid metabolism and thermogenesis (71).”
BackgroundObesity and the kidney: mechanistic links and therapeutic advances
Yau, K., Kuah, R., Cherney, D. Z. I., & Lam, T. K. T. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-00951-7 · Cited by 91
“Triple agonists that target GLP1, GIP and glucagon receptors with the aim of further reducing food intake and weight loss are under evaluation 112 .”
Richards, P., Thornberry, N. A., & Pinto, S. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101175 · Cited by 93
Oxyntomodulin: actions and role in diabetes
Holst, J. J., Albrechtsen, N. J. W., Gabe, M. B. N., & Rosenkilde, M. M. (2018) · Peptides · doi:10.1016/j.peptides.2017.09.018 · Cited by 86
“It has also been possible to modify the co-agonists to provide degradation resistance and long half-lives, and such co-agonists are currently in clinical development [79,80].”
Nongonierma, A. B., Dellafiora, L., Paolella, S., Galaverna, G., Cozzini, P., & Fitzgerald, R. J. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00329 · Cited by 86
“In addition, GLP-1 has been shown to modulate energy homeostasis by slowing down gastric emptying, inducing satiety, and reducing food intake (3).”
BackgroundThe molecular pharmacology of glucagon agonists in diabetes and obesity
Novikoff, A., & Müller, T. D. (2023) · Peptides · doi:10.1016/j.peptides.2023.171003 · Cited by 82
“novel GLP-1R/GcgR dual-agonists, GLP-1R/gastric inhibitory peptide (GIP) receptor dual-agonists have experienced profound success in the treatment of T2D and obesity [128,159,18].”
Self-citationStriking the balance: GLP-1/glucagon co-agonism as a treatment strategy for obesity
Hope, D. C. D., Vincent, M. L., & Tan, T. M. M. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.735019 · Cited by 81
“To plug this gap, researchers have pursued the ‘co-agonist’ strategy by combining GLP-1 with related hormones from the proglucagon family and related peptides, including GIP and glucagon itself (5).”
BackgroundPathogenesis of Nonalcoholic Steatohepatitis and Hormone-Based Therapeutic Approaches
Kim, K. H., & Lee, M. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00485 · Cited by 84
“Glucagon/GLP-1 receptor dual agonists and glucagon/glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor triple agonists are attractive therapeutic agents to treat NAFLD/NASH as well as obesity-related diabetes (123, 124).”
BackgroundAmbery, P. D., Klammt, S., Posch, M. G., Petrone, M., Pu, W., Rondinone, C., Jermutus, L., & Hirshberg, B. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13688 · Cited by 75
Bays, H. E., Fitch, A., Christensen, S., Burridge, K., & Tondt, J. (2022) · Obesity Pillars · doi:10.1016/j.obpill.2022.100018 · Cited by 68
Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH
Svegliati-Baroni, G., Patrício, B., Lioci, G., Macedo, M. P., & Gastaldelli, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165820 · Cited by 66
Hepatic glucagon action: beyond glucose mobilization
Kajani, S., Laker, R. C., Ratkova, E. L., Will, S., & Rhodes, C. J. (2024) · Physiological Reviews · doi:10.1152/physrev.00028.2023 · Cited by 72
Role of Glucagon and Its Receptor in the Pathogenesis of Diabetes
Jia, Y., Liu, Y., Feng, L., Sun, S., & Sun, G. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.928016 · Cited by 68
Obesity medications in development
Rebello, C. J., & Greenway, F. L. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1705277 · Cited by 62
Direct effects of glucagon on glucose uptake and lipolysis in human adipocytes
Pereira, M. J., Thombare, K., Sarsenbayeva, A., Kamble, P. G., Almby, K., Lundqvist, M., & Eriksson, J. W. (2020) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2019.110696 · Cited by 54
The Gut Microbiome in Human Obesity: A Comprehensive Review
Borrego-Ruiz, A., & Borrego, J. J. (2025) · Biomedicines · doi:10.3390/biomedicines13092173 · Cited by 66
“The therapeutic potential of GLP-1R/GcgR co-agonism in obesity management has been underscored by studies evaluating its effects in combination with leptin therapy [209].”
Altered glucose metabolism after bariatric surgery: What's GLP-1 got to do with it?
Smith, E. P., Polanco, G., Yaqub, A., & Salehi, M. (2017) · Metabolism · doi:10.1016/j.metabol.2017.10.014 · Cited by 54
Evers, A., Bossart, M., Pfeiffer-Marek, S., Elvert, R., Schreuder, H., Kurz, M., Stengelin, S., Lorenz, M., Herling, A., Konkar, A., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00292 · Cited by 50
Chimeric peptide EP45 as a dual agonist at GLP-1 and NPY2R receptors
Chepurny, O. G., Bonaccorso, R. L., Leech, C. A., Wöllert, T., Langford, G. M., Schwede, F., Roth, C. L., Doyle, R. P., & Holz, G. G. (2018) · Scientific Reports · doi:10.1038/s41598-018-22106-1 · Cited by 49
Schiavon, M., Visentin, R., Göbel, B., Riz, M., Cobelli, C., Klabunde, T., & Dalla Man, C. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14394 · Cited by 49
Knerr, P. J., Mowery, S. A., Finan, B., Perez-Tilve, D., Tschöp, M. H., & DiMarchi, R. D. (2020) · Peptides · doi:10.1016/j.peptides.2019.170225 · Cited by 49
Self-citationStructural analysis of the dual agonism at GLP-1R and GCGR
Li, Y., Zhou, Q., Dai, A., Zhao, F., Chang, R., Ying, T., Wu, B., Yang, D., Wang, M., & Cong, Z. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2303696120 · Cited by 50
“As a result, several GLP-1R/GCGR dual agonists designed based on the glucagon sequence by residue substitutions from GLP-1 or related peptides (15–17), such as peptide 15 (18), MEDI0382 and SAR425899, were developed.”
Friedrichsen, M. H., Endahl, L., Kreiner, F. F., Goldwater, R., Kankam, M., Toubro, S., & Nygård, S. B. (2023) · Molecular Metabolism · doi:10.1016/j.molmet.2023.101801 · Cited by 46
“Combining both glucagon receptor and GLP-1 receptor agonism in a single molecule could target weight loss through multiple mechanisms of action to enhance the level of weight loss possible [18].”
BackgroundEriksson, O., Haack, T., Hijazi, Y., Teichert, L., Tavernier, V., Laitinen, I., Berglund, J. E., Antoni, G., Velikyan, I., Johansson, L., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-73815-5 · Cited by 46
McElroy, S. L., Mori, N. N., Guerdjikova, A. I., & Keck, P. E. (2018) · Medical Hypotheses · doi:10.1016/j.mehy.2017.12.029 · Cited by 47
Abraham, M. A., & Lam, T. K. T. (2016) · Diabetologia · doi:10.1007/s00125-016-3950-3 · Cited by 49
Cryo-electron microscopy structure of the glucagon receptor with a dual-agonist peptide
Chang, R., Zhang, X., Qiao, A., Dai, A., Belousoff, M. J., Tan, Q., Shao, L., Zhong, L., Lin, G., Liang, Y.-L., et al. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.013793 · Cited by 39
“The peptide had approximately equal potency to GLP-1(7-36)NH2 in CHO-K1 cells expressing the WT human GLP-1R (Fig.”
BackgroundContemporary Classification of Glucagon-Like Peptide 1 Receptor Agonists (GLP1RAs)
Kalra, S., Bhattacharya, S., & Kapoor, N. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01113-y · Cited by 38
Chepurny, O. G., Matsoukas, M.-T., Liapakis, G., Leech, C. A., Milliken, B. T., Doyle, R. P., & Holz, G. G. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.005682 · Cited by 41
Milliken, B. T., Elfers, C., Chepurny, O. G., Chichura, K. S., Sweet, I. R., Borner, T., Hayes, M. R., Jonghe, B. C. D., Holz, G. G., Roth, C. L., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01783 · Cited by 41
Ullah, M. I., & Tamanna, S. (2025) · Medicines · doi:10.3390/medicines12030019 · Cited by 38
“Amylin, co-released with insulin from β -cells, likewise slows gastric emptying, suppresses glucagon, and enhances fullness to aid appetite control [62].”
Advances in GLP-1 receptor targeting radiolabeled agent development and prospective of theranostics
Velikyan, I., & Eriksson, O. (2019) · Theranostics · doi:10.7150/thno.38366 · Cited by 40
“It resulted in several anti-diabetic drugs (exenatide/AstraZeneca, liraglutide/Novo Nordisk, taspoglutide/IpsenRoche, lixisenatide/Sanofi-Aventis, semaglutide/ Novo Nordisk, albiglutide/GalxoSmithKline) based on GLP-1 analogs that stimulate insulin biosynthesis and secretion dependent on the blood glucose level and re…”
BackgroundGlucagon-based therapy: Past, present and future
Patil, M., Deshmukh, N., Patel, M. V., & Sangle, G. V. (2020) · Peptides · doi:10.1016/j.peptides.2020.170296 · Cited by 37
The Role of the α Cell in the Pathogenesis of Diabetes: A World beyond the Mirror
Martínez, M. S., Manzano, A., Olivar, L. C., Nava, M., Salazar, J. J., D’Marco, L., Ortíz, R., Chacín, M., Guerrero‐Wyss, M., de Bravo, M. C., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179504 · Cited by 42
Visentin, R., Schiavon, M., Göbel, B., Riz, M., Cobelli, C., Klabunde, T., & Dalla Man, C. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13939 · Cited by 37
De Block, C. E. M., Dirinck, E., Verhaegen, A., & Van Gaal, L. F. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14640 · Cited by 29
“This led to the development of a variety of unimolecular GLP-1/glucagon receptor (GLP-1/GCGR) dual agonists, based on the native peptides (glucagon, GLP-1, oxyntomodulin, exendin) as a starting template to design novel co-agonists.(54,55) Several dual GLP-1/GCGR agonists are being tested in phase 1 and 2 trials, inclu…”
BackgroundGLP-1 mimetics as a potential therapy for nonalcoholic steatohepatitis
Chen, Y., Xu, Y.-N., Ye, C.-Y., Feng, W., Zhou, Q., Yang, D., & Wang, M. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00836-9 · Cited by 34
“Combination of both resulted in a profound therapeutic superiority in reducing body weight, hyperglycemia and hepatic lipids beyond GLP-1R agonist alone [38, 122].”
BackgroundTwo weeks of exercise training intensity on appetite regulation in obese adults with prediabetes
Heiston, E. M., Eichner, N. Z. M., Gilbertson, N. M., Gaitán, J. M., Kranz, S., WELTMAN, A. L., & Malin, S. K. (2019) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00655.2018 · Cited by 34
“The initiation of fullness after a meal is to some extent mediated by glucagon-like peptide-1 (GLP-1) (5), an incretin hormone that slows the rate of gastric emptying, enhances satiety (48), and raises insulin secretion (34).”
BackgroundDagpo, T., Nolan, C. J., & Delghingaro‐Augusto, V. (2020) · Cells · doi:10.3390/cells9071596 · Cited by 35
“In recent years, technological advances in drug discovery has led to the development of a series of peptide hormone receptor co-agonists, including several GLP-1/glucagon and GLP-1/gastrointestinal insulinotropic polypeptide (GIP) receptor co-agonists, that have potent anti-obesity effects and are in various phases of…”
BackgroundNo Guts, No Loss: Toward the Ideal Treatment for Obesity in the Twenty-First Century
Hope, D. C. D., Tan, T., & Bloom, S. R. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00442 · Cited by 38
“Given the positive findings from these studies, several clinical trials of GLP-1/glucagon co-agonists are being carried out by a variety of pharmaceutical companies (82).”
BackgroundA GLP‐1/glucagon (GCG)/CCK2 receptors tri‐agonist provides new therapy for obesity and diabetes
Zhao, S., Yan, Z., Du, Y., Li, Z., Tang, C., Jing, L., Sun, L., Yang, Q., Tang, X., Yuan, Y., et al. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15860 · Cited by 30
“…level of body weight reduction effects in humans through increased energy expenditure and decreased food intake and the hyperglycaemic effects of glucagon (GCG) receptor activation were counteracted by the anti-diabetic effects of GLP-1 via GLP-1 receptor activation (Sánchez-Garrido et al., 2017).”
BackgroundKokkinos, A. D., Tsilingiris, D., le Roux, C. W., Rubino, F., & Mantzoros, C. S. (2019) · Metabolism · doi:10.1016/j.metabol.2019.153960 · Cited by 29
Glucagon receptor signaling in metabolic diseases
Albrechtsen, N. J. W. (2018) · Peptides · doi:10.1016/j.peptides.2017.11.016 · Cited by 29
“Whereas agonism of the glucagon receptor (GCGr) is commonly used for treatment of hypoglycemia in patients with type 1 diabetes [2,3] and potentially as a weight-lowering drug for obese individuals [4], antagonizing the GCGr on the other hand has been suggested a novel drug candidate for treatment of type 2 diabetes […”
McGlone, E. R., Manchanda, Y., Jones, B. J., Pickford, P., Inoue, A., Carling, D., Bloom, S. R., Tan, T., & Tomás, A. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101296 · Cited by 27
“Type 2 diabetes mellitus (T2DM) and non-alcoholic fatty liver disease (NAFLD) are characterised by high GCG levels and GCG resistance [5,6]; manipulation of GCG signalling is a potential pharmacological strategy for the treatment of these conditions [7,8].”
Chen, X., Fu, J., Zhou, F. L., Yang, Q., Wang, J., Feng, H., Jiang, W., Jin, L., Tang, X., Jiang, N., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00736 · Cited by 26
Gq signaling in α cells is critical for maintaining euglycemia
Liu, L., Dattaroy, D., Simpson, K. F., Barella, L. F., Cui, Y., Xiong, Y., Jin, J. J., König, G. M., Kostenis, E., ROMAN, J., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.152852 · Cited by 28
“with exendin(9-39) (Ex-9, 50 μg/mouse) 15 min prior to i.”
InfluentialChichura, K. S., Elfers, C., Salameh, T. S., Kamat, V., Chepurny, O. G., McGivney, A., Milliken, B. T., Holz, G. G., Applebey, S. V., Hayes, M. R., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-36178-1 · Cited by 27
Perspectives in weight control in diabetes - survodutide
Klein, T., Augustin, R., & Hennige, A. M. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110779 · Cited by 25
Muzurović, E. M., Katsiki, N., Volčanšek, Š., Plescia, F., Rizzo, M., & Mantzoros, C. S. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156494 · Cited by 25
Elvert, R., Bossart, M., Herling, A. W., Weiss, T., Zhang, B., Kannt, A., Wagner, M., Haack, T., Evers, A., Dudda, A., et al. (2018) · Endocrinology · doi:10.1210/en.2018-00399 · Cited by 24
Pharmacological profile of once-weekly injectable semaglutide for chronic weight management
Lau, D. C. W., Batterham, R. L., & le Roux, C. W. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2070473 · Cited by 27
“Another class of co-agonists, the dual GLP-1 and glucagon receptor co-agonist, is currently in phase 1 and 2 clinical trials [65,66].”
BackgroundValdecantos, M. P., Ruiz, L., Folgueira, C., Rada, P., Gómez‐Santos, B., Solas, M., Hitos, A. B., Field, J., Francisco, V., Escalona-Garrido, C., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54080-w · Cited by 24
“After washing with Tris-buffered saline (TBS)-0.05% Tween-20 (TBS-T), membranes were blocked with 6% skimmed milk powder in TBS-T buffer for 2 h at RT and incubated with primary antibodies (Supplementary Data 1) at 4 °C waving o/n.”
InfluentialSignaling profiles in HEK 293T cells co-expressing GLP-1 and GIP receptors
Wang, Y., Yang, D., & Wang, M. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00758-6 · Cited by 25
Management of Lifestyle Factors in Individuals with Cirrhosis: A Pragmatic Review
Tandon, P., & Berzigotti, A. (2019) · Seminars in Liver Disease · doi:10.1055/s-0039-1696639 · Cited by 25
The Fight Against Obesity Escalates: New Drugs on the Horizon and Metabolic Implications
Tsilingiris, D., Liatis, S., Dalamaga, Μ., & Kokkinos, A. D. (2020) · Current Obesity Reports · doi:10.1007/s13679-020-00378-x · Cited by 23
Managing weight and glycaemic targets in people with type 2 diabetes—How far have we come?
Blüher, M., Ceriello, A., Davies, M., Rodbard, H., Sattar, N., Schnell, O., Tonchevska, E., & Giorgino, F. (2022) · Endocrinology, Diabetes & Metabolism · doi:10.1002/edm2.330 · Cited by 20
Obesity and diabetes: the final frontier
Rendell, M. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2168643 · Cited by 23
Hasib, A., Ng, M. T., Tanday, N., Craig, S. L., Gault, V. A., Flatt, P. R., & Irwin, N. (2018) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3106 · Cited by 22
First-in-class positron emission tomography tracer for the glucagon receptor
Velikyan, I., Haack, T., Bossart, M., Evers, A., Laitinen, I., Larsen, P. J., Plettenburg, O., Johansson, L., Pierrou, S. E., Wagner, M., et al. (2019) · EJNMMI Research · doi:10.1186/s13550-019-0482-0 · Cited by 21
Time to Insulin Initiation in Type 2 Diabetes Patients in 2010/2011 and 2016/2017 in Germany
Kostev, K., Gölz, S., Scholz, B.-M., Kaiser, M., & Pscherer, S. (2019) · Journal of Diabetes Science and Technology · doi:10.1177/1932296819835196 · Cited by 23
“GLP-1-RA are associated with a weight reduction in T2D patients.(9) Several Cardiovascular Outcome Studies in patients with type 2 diabetes had a profound impact on recent treatment guidelines.”
BackgroundVincent, R. K., Williams, D. M., & Evans, M. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14196 · Cited by 22
“56 Indeed, reduced glucagon receptor signalling increases hepatic fat accumulation, 57 and use of glucagon antagonists in people with T2D increases hepatic fat.”
BackgroundCharacterisation and antidiabetic utility of a novel hybrid peptide, exendin-4/gastrin/xenin-8-Gln
Hasib, A., Ng, M. T., Khan, D., Gault, V. A., Flatt, P. R., & Irwin, N. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.07.027 · Cited by 20
Adrenomedullin and glucagon-like peptide-1 have additive effects on food intake in mice
Bech, E. M., Voldum-Clausen, K., Pedersen, S. L., Fabricius, K., Rudkjær, L. C. B., Hansen, H. H., & Jelsing, J. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.10.040 · Cited by 18
Sha, S., Liu, X., Zhao, R., Li, Q., He, Q., Sun, L., & Chen, L. (2019) · Endocrine · doi:10.1007/s12020-019-02081-x · Cited by 19
Design of novel Xenopus GLP-1-based dual glucagon-like peptide 1 (GLP-1)/glucagon receptor agonists
Jiang, N., Jing, L., Li, Q., Su, S.-B., Yang, Q., Zhou, F. L., Chen, X., Han, J. D. J., Tang, C., & Tang, W. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.113118 · Cited by 20
Designing poly-agonists for treatment of metabolic diseases: challenges and opportunities
Petersen, J., Strømgaard, K., Frølund, B., & Clemmensen, C. (2019) · Drugs · doi:10.1007/s40265-019-01153-6 · Cited by 17
Self-citationCosta, I. M., de Almeida, J. D., da Costa, K. M., Jardim, L. F. S., Rosa, M. J. D. S., Pifano, P. P., de Oliveira, R. R., Silva, S. O., Lima, S. D. S., & Godoy, J. T. (2021) · Brazilian Journal of Health Review · doi:10.34119/bjhrv4n2-022 · Cited by 79
ENOblock inhibits the pathology of diet-induced obesity
Cho, H., Lee, J., Um, J., Kim, S., Kim, Y., Kim, W., Kim, Y. S., Pagire, H. S., Ahn, J. H., Ahn, Y., et al. (2019) · Scientific Reports · doi:10.1038/s41598-018-36715-3 · Cited by 17
Biology and Clinical Use of Glucagon-Like Peptide-1 Receptor Agonists in Vascular Protection
Yau, K., Odutayo, A., Dash, S., & Cherney, D. Z. I. (2023) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2023.07.007 · Cited by 22
Graham, G. V., Conlon, J. M., Abdel‐Wahab, Y. H. A., & Flatt, P. R. (2018) · Peptides · doi:10.1016/j.peptides.2018.10.013 · Cited by 17
“A major advantage of administration of these multi-agonist peptides over their constituent monotherapies is their improved actions on blood glucose control, appetite, suppression, weight loss and hyperlipidemia/hypercholesterolemia although some patients have exhibited adverse effects including diarrhoea, nausea and d…”
Glucagon modulates proliferation and differentiation of human adipose precursors
Cantini, G., Trabucco, M., Franco, A. D., Mannucci, E., & Luconi, M. (2019) · Journal of Molecular Endocrinology · doi:10.1530/jme-19-0095 · Cited by 17
Liu, L., Rashid, M., & Wess, J. (2025) · Biochemistry · doi:10.1021/acs.biochem.4c00867 · Cited by 16
Khajavi, N., Finan, B., Kluth, O., Müller, T. D., Mergler, S., Schulz, A., Kleinau, G., Scheerer, P., Schürmann, A., Gudermann, T. W., et al. (2018) · Cellular Signalling · doi:10.1016/j.cellsig.2018.07.006 · Cited by 18
Self-citationGlucagon-Like Peptide-1 Receptor Agonists—Use in Clinical Practice
Tricò, D., & Solini, A. (2021) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2021.04.002 · Cited by 15
Arjmand, G., Abbaszadeh, M., Fardaei, M., & Eftekhari, M. H. (2022) · PubMed Central · doi:10.30476/ijms.2021.90829.2180 · Cited by 16
Quiñones, M., Fernø, J., Diéguez, C., Nogueiras, R., & Al–Massadi, O. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1583642 · Cited by 14
“been extensively reviewed [12,31,61,104], we will in this sec-”
BackgroundInfluential
Metadata
- Authors
- Sánchez-Garrido, M. A., Brandt, S. J., Clemmensen, C., Müller, T. D., DiMarchi, R. D., & Tschöp, M. H.
- Affiliations
- Helmholtz Munich (DE)
- Indiana University Bloomington (US)
- Corresponding author
- DiMarchi, Richard D.
- Tschöp, Matthias H.
- Venue
- Diabetologia
- Published
- 2017-07-21
- Volume
- 60
- Issue
- 10
- Pages
- 1851-1861
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- PMC
- PMC6448809
- OpenAlex
- W2737611067
- Cited by
- 175
- References
- 97
- Citations by year
- 2026: 19 · 2025: 15 · 2024: 13 · 2023: 22 · 2022: 15 · 2021: 23 · 2020: 17 · 2019: 25 · 2018: 23 · 2017: 2
- FWCI
- 2.36
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Diabetologia (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Site cant be reached (submittedVersion, other-oa)
- Funders
- Alexander von Humboldt-Stiftung
- Lundbeckfonden (R210-2015-4001)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- GLP-1 receptor, glucagon receptor, dual agonist, obesity, type 2 diabetes, anti-obesity drugs, peptide therapeutics, polypharmacy, bariatric surgery, weight loss
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Humans, Obesity, Receptors, Glucagon, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.